首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Dehydrodieugenol B derivatives as antiparasitic agents: Synthesis and biological activity against Trypanosoma cruzi
【24h】

Dehydrodieugenol B derivatives as antiparasitic agents: Synthesis and biological activity against Trypanosoma cruzi

机译:脱氢益丁烯醇B衍生物作为抗披啶药:对锥虫瘤Cruzi的合成和生物活性

获取原文
获取原文并翻译 | 示例
           

摘要

Chagas disease is a neglected protozoan disease that affects more than eight million people in developing countries. Due to the limited number and toxicity profiles of therapies in current use, new drugs are urgently needed. In previous studies, we reported the isolation of two related antitrypanosomal neolignans from Nectandra leucantha (Lauraceae). In this work, a semi-synthetic library of twenty-three neolignan derivatives was prepared to explore synthetically accessible structure activity relationships (SAR) against Trypanosoma cruzi. Five compounds demonstrated activity against trypomastigotes (IC50 values from 8 to 64 mu M) and eight showed activity against intracellular amastigotes (IC50 values from 7 to 16 M). Eighteen derivatives demonstrated no mammalian cytotoxicity up to 200 mu M. The phenolic acetate derivative of natural dehydrodieugenol B was effective against both parasite forms and eliminated 100% of amastigotes inside macrophages. This compound caused rapid and intense depolarization of the mitochondrial membrane potential, with decreased levels of intracellular reactive oxygen species being observed. Fluorescence assays demonstrated that this derivative affected neither the permeability nor the electric potential of the parasitic plasma membrane, an effect also corroborated by scanning electron microscopy studies. Structure-activity relationship studies (SARs) demonstrated that the presence of at least one allyl side chain on the biaryl ether core was important for antitrypanosomal activity, and that the free phenol is not essential. This set of neolignan derivatives represents a promising starting point for future Chagas disease drug discovery studies. (C) 2019 Elsevier Masson SAS. All rights reserved.
机译:Chagas疾病是一种被忽视的原生动物疾病,影响发展中国家超过800万人。由于目前使用的疗法数量和毒性有限,迫切需要新的药物。在以往的研究中,我们报告了来自Nectandra Leucantha(Lauraceae)的两种相关的抗酸酯组织Neolignans。在这项工作中,准备探讨促曲线瘤Cruzi的合成可接近的结构活动关系(SAR)的半合成文库。五种化合物证明了对胰蛋白酶的活性(IC 50值,从8至64μm的IC 50值),8例患有细胞内菌的活动(IC 50值为7-16μm)。十八衍生物证明没有哺乳动物细胞毒性高达200μm。天然脱水蛋白B的酚醋酸酯衍生物对寄生虫形成有效,并在巨噬细胞内消除了100%的Amastigotes。这种化合物引起线粒体膜电位的快速和强烈的去极化,观察到细胞内反应性氧的水平降低。荧光测定证明,该衍生物既不影响寄生素膜的电位,也通过扫描电子显微镜研究效果。结构 - 活性关系研究(SARS)证明了芳基醚核心上的至少一个烯丙基侧链对抗核糖体活性很重要,并且游离苯酚不是必需的。这套Neolignan衍生品代表了未来的Chagas病毒发现研究的有希望的起点。 (c)2019年Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号